Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic D

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic D
(NASDAQ: ARQT) Delayed: 25.38 -1.08 (4.08%)
Previous Close $26.46    52 Week High $ 
Open $26.14    52 Week Low $ 
Day High $26.75    P/E N/A 
Day Low $25.13    EPS $ 
Volume 19,137,078       

(NASDAQ: ARQT) Delayed: 25.38 -1.08 (4.08%)
Previous Close $26.46    52 Week High $ 
Open $26.14    52 Week Low $ 
Day High $26.75    P/E N/A 
Day Low $25.13    EPS $ 
Volume 19,137,078